Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy
Y Ali, S Abd Hamid - Tumor Biology, 2016 - Springer
Topoisomerases are nuclear enzymes that regulate topology of DNA by facilitating the
temporary cleavage and ligation cycle of DNA. Among all forms of topoisomerases, TOP-IIA …
temporary cleavage and ligation cycle of DNA. Among all forms of topoisomerases, TOP-IIA …
Microvessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer …
B Biesaga, J Niemiec, M Ziobro - Pathology & Oncology Research, 2012 - Springer
A considerable subgroup of patients with early breast cancer does not address benefits of
anthracycline based chemotherapy. The aim of this retrospective study was to investigate …
anthracycline based chemotherapy. The aim of this retrospective study was to investigate …
The predictive and prognostic significance of pre-and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast …
S Chen, L Huang, Y Liu, CM Chen, J Wu… - European Journal of …, 2013 - Elsevier
OBJECTIVE: To investigate the predictive and prognostic value of topoisomerase IIα (Topo
IIα, Topo II) expression in the primary tumors and residual tumors of local advanced breast …
IIα, Topo II) expression in the primary tumors and residual tumors of local advanced breast …
[HTML][HTML] Topoisomerase IIα immunoexpression in feline mammary carcinomas: A correlation with Ki67 immunoexpression and the mitotic count
W Łopuszyński, A Brzana, M Szczubiał, K Bulak… - Research in Veterinary …, 2023 - Elsevier
The aim of the study was to compare the immunohistochemical expression of topoisomerase
IIα protein (Topo IIα) with Ki67 expression and mitotic count in feline mammary carcinomas …
IIα protein (Topo IIα) with Ki67 expression and mitotic count in feline mammary carcinomas …
[PDF][PDF] Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline-and taxane-based chemotherapy
A Lee, W Lim, BI Moon, NS Paik… - Journal of breast …, 2011 - synapse.koreamed.org
Purpose: A chemotherapy response assay test is performed to evaluate the degree of tumor
growth inhibition by a chemotherapeutic agent. Several studies have been done on its …
growth inhibition by a chemotherapeutic agent. Several studies have been done on its …
[HTML][HTML] 浸润性乳腺癌组织HER2 与Ki67 联合表达与蒽环类化疗药物的疗效及预后相关
赵伟志， 赵薇， 杨小兵， 赵坤 - 南京医科大学学报(自然科学版), 2021 - jnmu.njmu.edu.cn
目的: 探讨浸润性乳腺癌组织中HER2 与Ki67 的表达与蒽环类化疗药物疗效及临床预后的相关
性. 方法: 数据库预测HER2 基因在浸润性乳腺癌组织中的表达情况及与Ki67 的关联性分析; …
性. 方法: 数据库预测HER2 基因在浸润性乳腺癌组织中的表达情况及与Ki67 的关联性分析; …
Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin
R Sakurai, K Kaira, Y Miura, N Sunaga, R Saito… - Thoracic …, 2020 - Wiley Online Library
Background Amrubicin chemotherapy is a treatment option for patients with non‐small cell
lung cancer (NSCLC) after third‐line treatment in Japan. Although topoisomerase‐II (Topo …
lung cancer (NSCLC) after third‐line treatment in Japan. Although topoisomerase‐II (Topo …
BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy
B Biesaga, J Niemiec, M Ziobro - Journal of cancer research and clinical …, 2014 - Springer
Purpose The aim of this retrospective study was to investigate the effect of B cell lymphoma
2 (BCL-2) expression on disease-free survival (DFS) in 172 early breast cancer (BC) …
2 (BCL-2) expression on disease-free survival (DFS) in 172 early breast cancer (BC) …
The predictive and prognostic role of topoisomerase IIα and tissue inhibitor of metalloproteinases 1 expression in locally advanced breast carcinoma of egyptian …
HS El Rebey, HAS Aiad, IL Abulkheir… - Applied …, 2016 - journals.lww.com
Purpose: Locally advanced breast cancer (LABC) is a heterogeneous entity that remains a
clinical challenge. Anthracycline-based neoadjuvant chemotherapy has emerged as the …
clinical challenge. Anthracycline-based neoadjuvant chemotherapy has emerged as the …